Invest along side VC’s and PE for access to high return startup flow. 
- Biotech Companies Hunt for Cash as VC Funding Dries Up Bloomberg
- How 2 biotechs survived 2022’s rocky market—and why their CEOs see success on the horizon FierceBiotech
- Upstart Drug Companies Are Scrambling for Cash Bloomberg
- The Money Tree for Biotech Startups Loses Its Leaves Bloomberg
- View Full coverage on Google News
